The Complexities of Molecular Testing
Lawrence N. Shulman, MD, discusses molecular testing.
Lawrence N. Shulman, MD, Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses molecular testing.
Clinical Pearls:
- Molecular testing for all types of cancer is more complex than previously thought
- Physicians need to keep molecular testing guidelines current
- There are 60-70 different EGFR mutations and each mutation has different significance for different therapies
- Physicians learned at the 2013 Chemotherapy Foundation Symposium that patients with HER2 mutations in breast cancer will need different therapies than patients who have amplification or overexpression of HER2
Related Videos
Related Content
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024Article
In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
